We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
Read MoreHide Full Article
ResMed Inc. (RMD - Free Report) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
Last quarter, the company posted a positive earnings surprise of 4.29%. The four-quarter average earnings beat is 0.31%. Let's see how things are shaping up for this announcement.
Factors at Play
In the previously reported second quarter, ResMed’s masks segment saw 7% year-over-year decline in sales. The company has been particularly concerned about sluggish mask growth in the EMEA and APAC regions for quite some time now. Even though the AirFit F20 and AirFit N20 masks have been introduced in these regions, management expects the underperformance to continue in the third quarter of 2017 as well.
Meanwhile, the company generates a significant portion of its revenues from international sales. Therefore, currency headwinds continue to affect ResMed’s overseas sales.
Moreover, overall macroeconomic uncertainty is a major obstacle for growth. Thus, the company is cautiously handling its international operations.
Another factor which has been acting as a dampener for margins is its rising operating expenses. Management projects a further escalation in costs associated with product launches and legal expenses in the second half of 2017.
Also, the market for sleep-disordered breathing (SDB) products is highly competitive with respect to product price, features and reliability. Other challenges like competitive bidding and reimbursement pressure continue to hurt the stock.
On the bright side, ResMed continues to enjoy high demand for its SDB products. Recently, the company unveiled positive data related to its adaptive servo-ventilation (ASV) therapy’s ability to treat patients with sleep apnea. The company’s current endeavors to gain traction in the SDB market are expected to boost revenues.
ResMed is currently planning to expand its base in international markets. The company has seen growth in China buoyed by strong execution of integration plans and better team work. ResMed expects to maintain this bullish trend in the forthcoming quarters as well. Management is also currently focusing on consolidating its presence in Europe with respect to its life support ventilation and non-invasive ventilation solutions.
Earnings Whispers
Our proven model does not conclusively show that ResMed is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: ResMed has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 70 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ResMed has a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Hill-Rom Holdings Inc has an Earnings ESP of +1.27% and a Zacks Rank #2.
Syros Pharmaceuticals, Inc. (SYRS - Free Report) has an Earnings ESP of +3.85% and a Zacks Rank #2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
ResMed Inc. (RMD - Free Report) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
Last quarter, the company posted a positive earnings surprise of 4.29%. The four-quarter average earnings beat is 0.31%. Let's see how things are shaping up for this announcement.
Factors at Play
In the previously reported second quarter, ResMed’s masks segment saw 7% year-over-year decline in sales. The company has been particularly concerned about sluggish mask growth in the EMEA and APAC regions for quite some time now. Even though the AirFit F20 and AirFit N20 masks have been introduced in these regions, management expects the underperformance to continue in the third quarter of 2017 as well.
ResMed Inc. Price and EPS Surprise
ResMed Inc. Price and EPS Surprise | ResMed Inc. Quote
Meanwhile, the company generates a significant portion of its revenues from international sales. Therefore, currency headwinds continue to affect ResMed’s overseas sales.
Moreover, overall macroeconomic uncertainty is a major obstacle for growth. Thus, the company is cautiously handling its international operations.
Another factor which has been acting as a dampener for margins is its rising operating expenses. Management projects a further escalation in costs associated with product launches and legal expenses in the second half of 2017.
Also, the market for sleep-disordered breathing (SDB) products is highly competitive with respect to product price, features and reliability. Other challenges like competitive bidding and reimbursement pressure continue to hurt the stock.
On the bright side, ResMed continues to enjoy high demand for its SDB products. Recently, the company unveiled positive data related to its adaptive servo-ventilation (ASV) therapy’s ability to treat patients with sleep apnea. The company’s current endeavors to gain traction in the SDB market are expected to boost revenues.
ResMed is currently planning to expand its base in international markets. The company has seen growth in China buoyed by strong execution of integration plans and better team work. ResMed expects to maintain this bullish trend in the forthcoming quarters as well. Management is also currently focusing on consolidating its presence in Europe with respect to its life support ventilation and non-invasive ventilation solutions.
Earnings Whispers
Our proven model does not conclusively show that ResMed is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: ResMed has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 70 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ResMed has a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Galectin Therapautics, Inc. (GALT - Free Report) has an Earnings ESP of +13.33% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hill-Rom Holdings Inc has an Earnings ESP of +1.27% and a Zacks Rank #2.
Syros Pharmaceuticals, Inc. (SYRS - Free Report) has an Earnings ESP of +3.85% and a Zacks Rank #2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>